External validation of the modified Marsh and Schnider models for medium-chain triglyceride propofol in target-controlled infusion anesthesia

Table 3 Measured propofol concentrations during induction and recovery phases including at LOC and ROC times

Period	Measured plasma concentration (Cp, ug/ml) and time (min)	Modified Marsh model (n = 24)	Schnider model (n = 24)	P value
Induction phase	Cp at LOC	9.88 ± 7.00	2.65 ± 0.83	< 0.001
	LOC time from TCI start	0.97 ± 0.22	5.03 ± 3.77	< 0.001
	Cp at 10 min after TCI start	3.83 ± 1.00	3.75 ± 1.27	0.808
Recovery phase	Cp at TCI stop	1.73 ± 0.41	1.85 ± 0.44	0.342
	Cp at ROC	0.96 ± 0.23	0.97 ± 0.24	0.861
	ROC time from TCI stop	7.03 ± 5.83	7.88 ± 4.62	0.578
	Cp at 60 min after TCI stop	0.59 ± 0.15	0.58 ± 0.13	0.879

Data are presented as mean ± SD. During induction phase, an initial target Ce was 3.0 or 3.5 ug/ml and was not changed until 10 min after TCI start (Ce 3.5 for 6 patients for each model). At the end of surgery, TCI was stopped at Ce 2.0 or 2.2 ug/ml (Ce 2.2 for 6 patients for each model)
LOC Loss of consciousness, ROC Recovery of consciousness, TCI Target controlled infusion, Ce Effect-site concentration

ISSN: 1471-2253